

Neuronetics, Inc. Supplemental Financial and Operating Information
For the period ended December 31, 2022

\$000s

Revenue (\$ thousands)	2020				2021				2022				2020	2021	2022
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	FY	FY	FY
Total U.S. NeuroStar Advanced Therapy System Revenues	\$2,594	\$2,338	\$2,541	\$3,620	\$1,755	\$2,577	\$2,612	\$2,815	\$3,642	\$4,382	\$3,934	\$4,616	\$11,094	\$9,760	\$16,575
YoY Change	-23%	-49%	-45%	-33%	-32%	10%	3%	-22%	108%	70%	51%	64%	-38%	-12%	70%
Total U.S. Treatment Sessions Revenues	\$8,193	\$6,547	\$9,083	\$11,029	\$9,629	\$10,801	\$10,259	\$11,245	\$9,469	\$11,295	\$11,864	\$12,450	\$34,852	\$41,933	\$45,077
YoY Change	-7%	-40%	-11%	-2%	18%	65%	13%	2%	-2%	5%	16%	11%	-15%	20%	7%
Total U.S. Other Revenues	\$390	\$382	\$404	\$397	\$419	\$431	\$409	\$496	\$406	\$455	\$446	\$447	\$1,574	\$1,754	\$1,754
YoY Change	-7%	-8%	-5%	6%	7%	13%	1%	25%	-3%	6%	9%	-10%	-4%	12%	0%
Total U.S. Revenues	\$11,177	\$9,267	\$12,029	\$15,046	\$11,802	\$13,809	\$13,280	\$14,556	\$13,517	\$16,132	\$16,244	\$17,513	\$47,519	\$53,447	\$63,406
YoY Change	-11%	-42%	-21%	-12%	6%	49%	10%	-3%	15%	17%	22%	20%	-22%	12%	19%
Total International Revenues	\$299	\$474	\$419	\$533	\$486	\$394	\$519	\$466	\$664	\$198	\$253	\$686	\$1,725	\$1,865	\$1,800
YoY Change	64%	-31%	-41%	64%	63%	-17%	24%	-13%	36%	-50%	-51%	47%	-9%	8%	-3%
Total Revenues	\$11,476	\$9,741	\$12,448	\$15,579	\$12,288	\$14,203	\$13,799	\$15,022	\$14,181	\$16,329	\$16,498	\$18,198	\$49,244	\$55,312	\$65,206
YoY Change	-10%	-41%	-22%	-10%	7%	46%	11%	-4%	15%	15%	20%	21%	-21%	12%	18%
U.S. Operating and Financial Metrics	2020				2021				2022				2020	2021	2022
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	FY	FY	FY
Total NeuroStar Systems	38	35	39	54	23	36	40	48	46	59	50	58	166	147	213
YoY Change	-12%	-43%	-43%	-31%	-39%	3%	3%	-11%	100%	64%	25%	21%	-34%	-11%	45%
Average Revenue Per Active Site (\$) (1)	\$9,418	\$7,406	\$10,218	\$12,133	\$10,512	\$12,001	\$11,163	\$12,183	\$9,874	\$11,280	\$11,364	\$11,517			
YoY Change	-24%	-50%	-22%	-10%	12%	62%	9%	0.4%	-6%	-6%	2%	-5%			

(1) = Total U.S. Treatment Session Revenue / Active Sites (End of Prior Period)